Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mario Sznol

Showing results (11-20 of 188) with videos related to

Pageof 19
Sort By:
Cancer Journal (Sudbury, Mass.)|January 22, 2014
Expanded use trials-are there better approaches to minimize adverse consequences to the clinical trials program?Mario Sznol
Current Opinion in Investigational Drugs (London, England : 2000)|January 28, 2011
Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?Mario Sznol
Cancer Journal (Sudbury, Mass.)|January 24, 2018
Combination Strategies PD-1/PD-L1 AntagonistsMario Sznol
Journal for Immunotherapy of Cancer|January 7, 2023
Teaching an old dog new tricks: re-engineering IL-2 for immuno-oncology applicationsMario Sznol, Naiyer Rizvi
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 6, 2013
Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancerMario Sznol, Lieping Chen
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 20, 2013
Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer--responseMario Sznol, Lieping Chen
Seminars in Oncology|May 13, 2015
Therapeutic combinations of immune-modulating antibodies in melanoma and beyondJustine Cohen, Mario Sznol
Current Opinion in Immunology|March 6, 2021
Resistance mechanisms to checkpoint inhibitorsSarah A Weiss, Mario Sznol
The New England Journal of Medicine|December 9, 2014
Release the hounds! Activating the T-cell response to cancerMario Sznol, Dan L Longo
The Lancet. Oncology|November 8, 2016
Diminished but not dead: chemotherapy for the treatment of NSCLCRoy S Herbst, Mario Sznol
Pageof 19

Showing results (11-20 of 188) with videos related to

Sort By:
Pageof 19
Cancer Journal (Sudbury, Mass.)|January 22, 2014
Expanded use trials-are there better approaches to minimize adverse consequences to the clinical trials program?Mario Sznol
Current Opinion in Investigational Drugs (London, England : 2000)|January 28, 2011
Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?Mario Sznol
Cancer Journal (Sudbury, Mass.)|January 24, 2018
Combination Strategies PD-1/PD-L1 AntagonistsMario Sznol
Journal for Immunotherapy of Cancer|January 7, 2023
Teaching an old dog new tricks: re-engineering IL-2 for immuno-oncology applicationsMario Sznol, Naiyer Rizvi
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 6, 2013
Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancerMario Sznol, Lieping Chen
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 20, 2013
Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer--responseMario Sznol, Lieping Chen
Seminars in Oncology|May 13, 2015
Therapeutic combinations of immune-modulating antibodies in melanoma and beyondJustine Cohen, Mario Sznol
Current Opinion in Immunology|March 6, 2021
Resistance mechanisms to checkpoint inhibitorsSarah A Weiss, Mario Sznol
The New England Journal of Medicine|December 9, 2014
Release the hounds! Activating the T-cell response to cancerMario Sznol, Dan L Longo
The Lancet. Oncology|November 8, 2016
Diminished but not dead: chemotherapy for the treatment of NSCLCRoy S Herbst, Mario Sznol
Pageof 19